BRIEF—Post hoc analysis of Chiesi's Kengreal

The US subsidiary of Italian drugmaker Chiesi Farmaceutici has announced that a post hoc analysis of the CHAMPION PHOENIX clinical trial that evaluated treatment of Kengreal (cangrelor) in patients undergoing percutaneous coronary intervention (PCI) was published in Circulation: Cardiovascular Interventions.

The analysis found that the majority of ischemic events occurred early in PCI, and Kengreal treatment significantly reduced these events in the first two hours post-randomization compared to clopidogrel, the standard of care.

“These results demonstrate the importance of potent platelet inhibition during this critical window of treatment,” said Martin Marciniak, vice president and head of US medical affairs at Chiesi.

“We are thankful for the contributions of everyone who participated in this valuable analysis, and we’re committed to supporting advancements in interventional cardiology to improve care for cardiac patients,” he added.